Tibolone: A review

Maturitas

Volumn 30, Issue 3, 1998, Pages 295-305

  Albertazzi, Paola ^a   Di Micco, Raffaele ^a   Zanardi, Ettore ^a  

^a MAGGIORE HOSPITAL   (Italy)

Author keywords

Climacteric symptoms; Lipids; Livial; Osteoporosis; Tibolone

Indexed keywords

ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; TIBOLONE; TRIACYLGLYCEROL;

ACNE; AMENORRHEA; ANDROGEN THERAPY; BLOOD PRESSURE; BLOOD VESSEL REACTIVITY; BONE MASS; BONE METABOLISM; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLIMACTERIUM; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG INDICATION; DRUG METABOLISM; DRUG WITHDRAWAL; ENDOMETRIUM; FEMALE; FRACTURE; HEART OUTPUT; HIRSUTISM; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; LIBIDO; LIPOPROTEIN BLOOD LEVEL; MASTALGIA; MENOPAUSE; META ANALYSIS; OBESITY; ORAL DRUG ADMINISTRATION; PERIPHERAL CIRCULATION; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; VASODILATATION;

ANABOLIC AGENTS; BONE DENSITY; BREAST; FEMALE; HEMODYNAMIC PROCESSES; HORMONE REPLACEMENT THERAPY; HUMANS; LIPIDS; MENOPAUSE; NORPREGNENES; RANDOMIZED CONTROLLED TRIALS; UTERUS;

EID: 0032538825     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(98)00059-0     Document Type: Review

References (57)

1. Nessen T, Berglund L, Ulmsten U. Bone loss in elderly women prevented by ultralow doses of parenteral 17β-estradiol. Am J Obstet Gynecol. 177:1997;115-119.
2. Schiff I. Summing up the risk: benefit equation. Menopause. 3:1996;61-64.
3. Schneider DL, Barrett-Connor EL, Morton DJ. Timing of postmenopausal estrogen for optimal bone mineral density. J Am Med Assoc. 277:1997;543-547.
4. Vies J. Pharmacological studies with ORG Od 14. Maturitas 1987;1:15-24.
5. Organon International, Oss Scientific Dev. Data on file.
6. Benedek-Jazmann LJ. Long-term placebo-controlled efficacy and safety study of Org OD 14 in climacteric women. Maturitas. Suppl 1:1987;25-33.
7. DeAloysio D, Fabiani AG, Mauloni M, Bottiglioni F. Use of Org OD 14 for the treatment of climacteric complaints. Maturitas. Suppl 1:1987;49-65.
8. Linsday R, Hart DMcK, Kraszenwski A. Prospective double-blind trial of synthetic steroid (Or OD 14) for preventing postmenopausal osteoporosis. Br Med J 1980; 1207-9.
9. Kicovic PM, Cortes-Prieto J, Luisi M, Milojevic S, Franchi F. Placebo controlled cross-over study of effects of Org OD 14 in menopausal women. Reproduction. 6:1982;81-91.
10. Nevinny-Strickel J. Double-blind cross-over study with Org OD 14 and placebo in postmenopausal patients. Arch Gynecol. 234:1983;27-31.
11. Crona N, Samsioe G, Lindberg UB, Silfverstolpe G. Treatment of climacteric complaints with Org OD 14: a comparative study with oestradiol valerate and placebo. Maturitas. 9:1988;303-308.
12. Volpe A, Facchinetti F, Grasso A, Petraglia F, Campanini D, Genazzani AR Benefits and Risks of different hormonal replacement therapies in postmenopausal women. Maturitas. 8:1986;327-334.
13. Ross LA, Adler EM. Tibolone and climacteric symptoms. Maturitas. 2:1995;127-136.
14. Cittadini J, Ben J, Badano et al. The use of a new steroid (Org OD 14) in the climacteric syndrome. Reproduction 1982; 6: 69-79.
15. Egarter C, Huber J, Leikermoser, Haidbauer R, Push H, Fischl, Putz M. Tibolone versus conjugated estrogens and sequential progestogen in the treatment of climacteric complaints. Maturitas 1996; 23: 55-62.
16. Genazzani AR, Petraglia F, Facchinetti F, Genazzani AD, Bergamaschi M, Grasso A, Volpe A. Effects of Org OD 14 on pituitary and peripheral β-endorphin in castrated rats and postmenopausal women. Maturitas. Suppl 1:1987;35-48.
17. Genazzani AR, Petraglia F, Facchinetti F, Genazzani AD, Bergamaschi M, Grasso A, Volpe A. Steroid replacement treatment increases β-endorphin and β-lipotropin plasma levels in postmenopausal women. Gynecol Obstet Invest. 26:1988;153-159.
18. Montgomery J, Brincat M, Tapp A, Appleby L, Versi E, Fenwick PBC, Studd JWW. The effect of estrogen and testosterone implants on psychological disorders of the climacteric. Lancet. 1:1987;297-299.
19. Rymer J, Chapman MG, Fogelman I, Wilson POG. A study of the effect of tibolone on the vagina of postmenopausal women. Maturitas. 18:1994;127-133.
20. Nathorst-Boos J, Hammar M. Effect on sexual life - a comparison between tibolone and a continuous estradiol-norethisterone acetate regimen. Maturitas. 26:1997;15-20.
21. Punnonen R, Liukko P, Cortes-Prieto J et al. Multicentre study on the effects of ORG OD 14 on endometrium, vaginal cytology and cervical mucus in postmenopausal and oophorectomized women. Maturitas. 5:1984;281-286.
22. Genazzani AR, Benedek-Jaszman LJ, Hart DM, Andolsek L, Kicovic PM, Tax L ORG OD 14 and the endometrium. Maturitas 1991;13:243-51.
23. Trevoux R, Dieulangard P, Blum A. Efficacy and safety of ORG OG 14 in the treatment of climacteric complaints. Maturitas. 5:1983;89-96.
24. von Dadelszen P, Gillmer MDG, Gray MD, McEwan HP, Pyper RJD, Rollason TP, Wright A. Endometrial hyperplasia and adenocarcinoma during tibolone (Livial) therapy. Br Med J. 101:1994;158-161.
25. Botsis D, Kassanos D, Antoniou G, Vitoratos N, Karakitos P. Vaginal ultrasound of the endometrium in postmenopausal women with symptoms of urogenital atrophy on low-dose estrogen or tibolone treatment: a comparison. Maturitas. 26:1997;57-62.
26. Gregoriou O, Vitoratus N, Papdias C, Konidaris S, Costomenos D, Chryssikopoulos A. Effects of tibolone on postmenopausal women with myomas. Maturitas. 27:1997;187-191.
27. Senez AB, Seckin NC, Ozmen S, Gokmen O, Dogu N, Ekici E. The effects of hormonal replacement therapy on uterine fibroids in postmenopausal women. Fertil Steril. 65:1996;354-357.
28. Rymer J, Fogelman I, Chapman M.G. The incidence of vaginal bleeding with tibolone treatment. Br J Obstet Gynaecol. 101:1994;53-56.
29. Ginsburg J, Prelevic GM. Cause of vaginal bleeding in postmenopausal women taking tibolone. Maturitas. 24:1996;107-110.
30. Bjarnason NH, Bjarnason K, Haarbo J, Rosenquist C, Christiansen C. Tibolone: prevention of bone loss in late postmenopausal women. J Endocrinol Metab. 81:1996;2419-2422.
31. Berning B, Kuijk CV, Kuipper JW, Coelingh Bennink HJT, Kicovic PM, Fauser BCJM. Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: a 2-year randomised placebo-controlled study. Bone. 19:1996;395-399.
32. Ginsburg J, Prelevic G, Butler D, Okolo S. Clinical experience with tibolone over 8 years. Maturitas. 21:1995;71-76.
33. Kloosterboer HJ, Schoonen WGEJ, Deckers Gh, Klijn JGM. Effects of progestogens and Org Od 14 in vitro and in-vivo tumour model. J Steroid Biochem Mol Biol. 49:1994;311-318.
34. Milner MH, Sinnott MM, Cooke TM, Kelly A, McGill T, Harrison RF. A 2 years study of lipid and lipoprotein changes in postmenopausal women with tibolone and estrogen and progestogen. Obstet Gynecol. 87:1996;593-599.
35. Crona N, Silverstolpe G, Samsioe G. A double blind cross-over study on the effects of ORG OD 14 compared to oestradiol valerate and placebo on lipids and carbohydrate metabolism in oophorectomised women. Acta Endocrinol (Copenh). 102:1983;451-455.
36. Farish E, Barnes JF, Rolton HA, Spowart K, Fletcher CD, Hart DM. Effect of tibolone on lipoprotein (a) and HDL subfractions. Maturitas. 20:1995;215-219.
37. Hanggi W, Lippuner K, Riesen W, Jaeger P, Birkhauser MH. Long term influence of different postmenopasual hormone replacement regimens on serum lipids and lipoprotein (a): a randomised study. Br J Obstet Gynaecol. 104:1997;708-717.
38. Cagnacci A, Mallus E, Tuveri F, Cirillo R, Setteneri AM, Melis GB. The effect of tibolone on glucose and lipid metabolism in postmenopausal women. J Clin Endocrinol Metab. 82:1997;251-253.
39. Rosati D, Pinto S, Fedi S et al. Changes in lipid and haemodinamic parameters induced by tibolone treatment. Thrombosis Res. 85:1997;273-278.
40. Kloosterboer HJ, Benedek-Jazmann LJ, Kicovic PM. Long term effects of Org OD 14 on lipids metabolism in postmenopausal women. Maturitas. 12:1990;37-42.
41. Campos H, Roeder GO, Lussier Cacan S, Davignon J, Krauss RM. Predominance of large LDL and reduced HDL 2 cholesterol in normolipidemic men with coronary artery disease. Arterioscler Thromb Vasc Biol. 15:1995;1043-1048.
42. Stampfer MJ, Sacks FM, Simonetta S, Willett WC, Hennkens CH. A prospective study of cholesterol, apolipoproteins and the risk of myocardial infarction. New Engl J Med. 325:1991;373-381.
43. Crook D, Sihu M, O'Donnell M, Stevenson JC. Lp(a) levels in women given danazol, an impeded androgen. Atherosclerosis. 92:1992;41-47.
44. Cagnacci A, Mallus E, Tuveri F, Cirilllo R, Setteneri AM, Melis GB. Effect of tibolone on glucose metabolism in postmenopausal women. J Clin Edocrinol Metab. 82:1997;251-253.
45. Feher MD, Cox A, Levy A, Mayne P, Lant AF. Short term blood pressure and metabolic effects of tibolone in postmenopausal women with non-insulin dependent diabetes. Br J Gynaecol. 103:1996;281-283.
46. Prelevic G, Beljic T, Ginsburg J. The effect of tibolone on cardiac flow in postmenopausal women with non-insulin dependent diabetes mellitus. Maturitas. 27:1997;85-90.
47. Atsma WJ. Is livial diabetogenic? Maturitas. 19:1994;239-240.
48. Cortes-Prieto J. Coagulation and fibrinolysis in post-menopausal women treated with Org OD 14. Maturitas. Suppl:1987;67-72.
49. Walker ID, Davidson JF, Richards A, Yates R, Mc Ewan HP. The effect of the syntetic steroid Org OD 14 on fibrinolysis and blood lipids in postmenoapusal women. Thromb Haemost. 53:1985;303-305.
50. Crook D, Sidhu M, Seed M, O'Donnell M, Stevenson JC. Lipoprotein Lp(a) levels are reduced by danazol, an anabolic steroid. Arteriosclerosis. 92:1992;41-47.
51. Rymer J, Chapman MG, Foghelman I. Effect of tibolone on postmenopausal bone loss. Osteop Int. 4:1994;314-319.
52. Geusens P, Dequeker J, Gielen J, Schot LPC. Non-linear increase in vertebral density induced by a synthetic steroid (Org OD 14) in women with established osteoporosis. Maturitas. 13:1991;155-162.
53. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OM. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. New Engl J Med. 322:1990;1265-1271.
54. Linsday R, Hart DM, Krasewski A. Prospective double-blind trial of synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis. Br Med J. 280:1980;1207-1209.
55. Luisi M, Franchi F. Effects of 1.25 mg of Org Od 14 on the hypothalamic-pituitary-ovarian axis function and prolactin/thyrotropin responses to TRH in ovulatory women. 1997;Wesbury, Organon.
56. Lippuner K, Haenggi W, Birkhaeuser MH, Casez JP, Jaeger P. Prevention of Postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17β-estradiol and dydrogesterone. J Bone Miner Res. 12:1997;806-812.
57. Linsday R. Estrogen deficiency. Riggs BL, Melton LJ Osteoporosis: Ethiology, Diagnosis and Management. 1995;133-160 Lippincott-Raven Press, Philadelphia.